Associate Professor Peter Mollee
Associate Professor

Peter Mollee

Email: 

Background

Dr Mollee practices as a consultant haematologist in clinical and laboratory haematology at the Princess Alexandra Hospital and is Associate Professor with the University of Queensland Medical School.

Having trained in Brisbane and Toronto, Dr Mollee has developed an international reputation studying amyloidosis and the plasma cell dyscrasias. He holds appointments with the Medical Scientific Advisory Group of Myeloma Australia, Australian Amyloidosis Network, National Blood Cancer Taskforce and is a member of the AACB Monoclonal Gammopathy Working Group and the International Kidney & Monoclonal Gammopathy Research Group. He is a past Chairman of the Australasian Leukaemia and Lymphoma Group (ALLG) and current Chair of the Australian Amyloidosis Network. He heads the Myeloma Service as well as the Queensland Amyloidosis Centre which runs one of the few clinics in Australia dedicated exclusively to the care of patients with amyloidosis.

Availability

Associate Professor Peter Mollee is:
Available for supervision

Qualifications

  • Masters (Coursework) of Medical Science, University of Newcastle
  • Royal Australasian College of Physicians, Royal Australasian College of Physicians
  • Royal College of Pathologists of Australasia, Royal College of Pathologists of Australasia

Research impacts

The research of the Queensland Amyloidosis Centre aims to improved the diagnosis, monitoring and therapy of all types of amyloidosis. The Centre, in collaboration with Pathology Queensland and the Translational Research Institute, developed laser capture macrodisscution and tandem mass spectrometry analysis to accurately diagnosis the type of amyloidosis that patients have and have introuduced this assay into the clinical laboratory. Research to improve the diagnosis and monitoring of this rare disease has also assessed immunoglobulin free light chain assays, bone scintigraphy and novel radionuclide PET tracers. The Queensland Amyloidosis Centre maintains an active clinical trial program in amyloidosis therapies including both investigator-initiated and commercial studies.

Search Professor Peter Mollee’s works on UQ eSpace

179 works between 1999 and 2024
All (179) Journal Article (116) Conference Publication (61) Book Chapter (2)

161 - 179 of 179 works

Past funding

  • 2022 - 2023
    Laser capture microdissection to empower cancer discoveries, improve diagnosis, treatment and outcomes in amyloidosis patients
    IPF Healthy - Medical Research
    Open grant
  • 2019 - 2023
    Frailty-stratified randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma - the FRAIL-M study (MRFF LSCD Grant Administered by Monash)
    Monash University
    Open grant
  • 2018 - 2025
    An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab and EBV specific T-cells in Patients with EBV-positive Primary or Secondary CNS Lymphoma unsuitable for standard therapies
    NHMRC MRFF - Lifting Clinical Trials Registries Capacity
    Open grant
  • 2017 - 2021
    Benefit of 2D-strain surveillance in improving cardiovascular outcomes in cancer patients undergoing cardiotoxic chemotherapy
    Baker IDI Heart & Diabetes Institute
    Open grant
  • 2013 - 2020
    The Diamantina Individualised Oncology Care Centre (DIOCC)
    Australian Cancer Research Foundation
    Open grant
  • 2007
    Valproic acid and cytarabine therapy for elderly or relapsed acute myeloid leukaemia
    Leukaemia Foundation
    Open grant

Availability

Associate Professor Peter Mollee is:
Available for supervision

Looking for a supervisor? Read our advice on how to choose a supervisor.

Supervision history

Current supervision

Enquiries

For media enquiries about Associate Professor Peter Mollee's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au